The estetrol-drospirenone-containing contraceptive as a drug of choice for patients with mastalgia

The problem of mastalgia is widespread: up to 70% of women report regular or episodic pain in the mammary gland. The role of benign breast disease in the occurrence of these complaints was noted only in 10–30% of cases, while in most women mastalgia is a manifestation of premenstrual syndrome caused by excessive water retention in the body. As a therapy for such patients, the optimal solution would be to prescribe a new combined oral contraceptive containing 15 mg of estetrol and 3 mg of drospirenone. The uniqueness of this combination in this situation lies in the pronounced antimineralocorticoid effect of drospirenone, supported by a high safety profile of estetrol, including a reduced risk of developing breast cancer compared to other combined oral contraceptive. © 2023, LLC MMA MediaMedika. All rights reserved.